Screening of glucose metabolism derangements in pediatric cystic fibrosis patients: how, when, why.

Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9200299 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-5233 (Electronic) Linking ISSN: 09405429 NLM ISO Abbreviation: Acta Diabetol Subsets: MEDLINE

Publication: Berlin : Springer Verlag
Original Publication: Berlin : Springer International, c1991-

Cystic Fibrosis/*metabolism ; Glucose Intolerance/*diagnosis ; Mass Screening/*statistics & numerical data; Adolescent ; Child ; Child, Preschool ; Comorbidity ; Cystic Fibrosis/complications ; Cystic Fibrosis/diagnosis ; Cystic Fibrosis/epidemiology ; Diabetes Complications/blood ; Diabetes Complications/epidemiology ; Diabetes Mellitus/blood ; Diabetes Mellitus/diagnosis ; Diabetes Mellitus/epidemiology ; Glucose Intolerance/blood ; Glucose Intolerance/epidemiology ; Glucose Tolerance Test ; Humans

Diabetes mellitus is the most common comorbidity in cystic fibrosis (CF), occurring in a variable number of children and adolescents. Glucose metabolism derangements (GMDs) are responsible for a negative impact on the general health status of CF patients. Screening of GMDs is important since the youngest age and should be performed by means of OGTT, including its intermediate times, that could detect other non-traditional GMDs. Insulin treatment, administered before overt diabetes, could be beneficial in reducing the number of pulmonary infections, in improving both pulmonary function and nutritional status. Early screening of GMDs in pediatric age can exert an important preventing role regarding all aspects of health status of patients with CF.

Date Created: 20150413 Date Completed: 20161213 Latest Revision: 20181202

20240628

10.1007/s00592-015-0743-y

25863781